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In Brief
Pambianco et al. describe a specific
mitochondrial defect in LGMD-2D,
characterized by reduced mitochondrial
number. This defect is due to impaired
mitochondrial biogenesis associated with
condensed chromatin at the PGC-1a
promoter and is reversed by Trichostatin
A. Nitric oxide rescues the bioenergetics
defect without affecting mitochondrial
biogenesis.
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http://dx.doi.org/10.1016/j.celrep.2016.11.044SUMMARY
Mitochondrial dysfunction occurs in many muscle
degenerative disorders. Here, we demonstrate that
mitochondrial biogenesis was impaired in limb-girdle
muscular dystrophy (LGMD) 2D patients and mice
and was associated with impaired OxPhos capacity.
Two distinct approaches that modulated histones or
peroxisome proliferator-activated receptor-gamma
coactivator 1 a (PGC-1a) acetylation exerted equiva-
lent functional effects by targeting different mito-
chondrial pathways (mitochondrial biogenesis or
fatty acid oxidation[FAO]). The histone deacetylase
inhibitor Trichostatin A (TSA) changed chromatin
assembly at the PGC-1a promoter, restored mito-
chondrial biogenesis, and enhanced muscle oxida-
tive capacity. Conversely, nitric oxide (NO) triggered
post translation modifications of PGC-1a and
induced FAO, recovering the bioenergetics impair-
ment of muscles but shunting the defective mito-
chondrial biogenesis. In conclusion, a transcriptional
blockade of mitochondrial biogenesis occurred in
LGMD-2D and could be recovered by TSA changing
chromatin conformation, or it could be overcome by
NO activating a mitochondrial salvage pathway.
INTRODUCTION
Mitochondrial defects accompany several forms of muscular
dystrophies, genetic diseases characterized by progressive3010 Cell Reports 17, 3010–3023, December 13, 2016 ª 2016 The A
This is an open access article under the CC BY-NC-ND license (http://skeletal muscle wasting, local inflammation, and compensatory
regeneration (Barton et al., 2005; Kornegay et al., 2014; Ruegg,
2013). While loss of functional dystrophin protein is the primary
cause of Duchenne muscular dystrophy (DMD), other patho-
genic events have recently been associated with DMD, including
decreased mitochondrial mass (Godin et al., 2012) and reduced
expression of enzymes involved in glycolytic and oxidativemeta-
bolism (Guevel et al., 2011; Percival et al., 2013; Rybalka et al.,
2014). Likewise, in limb-girdle muscular dystrophy 2D (LGMD-
2D), loss of a sarcoglycan (a-SG), an essential component of
the dystrophin-glycoprotein complex, is accompanied with
reduced transcription of nuclear-encoded mitochondrial genes
similar to that observed in DMD (Chen et al., 2000; Pescatori
et al., 2007). This evidence indicates that metabolic dysregula-
tion is a pathogenic event shared by muscular dystrophies in
which deficiency of a component of the dystrophin-associated
complex can impair signaling to the mitochondria.
An important aspect in dystrophic skeletal muscle including
LGMD-2D (Crosbie et al., 2002) is the displacement of the mus-
cle-specific variant of the enzyme neuronal nitric oxide (NO)
synthase (nNOSm), usually localized at the sarcolemma in close
contact with the sarcoglycan-dystroglycan complex, with
reduced generation of NO. NO in skeletal muscle regulates
metabolism and energy expenditure, coupling energy demand
and supply through a variety of actions (De Palma and Clementi,
2012; Stamler and Meissner, 2001). In addition, NO stimulates
mitochondrial biogenesis (Nisoli et al., 2003, 2007), regulates
mitochondrial dynamics (De Palma et al., 2010), and contributes
to muscle physiological growth and repair via several actions
including inhibition of histone deacetylases (HDACs) (Colussi
et al., 2008, 2009; Tidball and Wehling-Henricks, 2014). Normal-
ization of NO production slows disease progression in mouseuthors.
creativecommons.org/licenses/by-nc-nd/4.0/).
models of muscular dystrophies and it is currently investigated in
therapeutic perspective (Brunelli et al., 2007; D’Angelo et al.,
2012; Sciorati et al., 2010).
Here, we characterize themitochondrial dysfunction in LGMD-
2D patients and in the a-SG mouse model of the disorder,
showing a defective OxPhos capacity, accompanied by persis-
tent impairment of mitochondrial biogenesis that could not be
reactivated by physiological mitochondrial biogenetic stimuli
such as cold. These defects coincided with formation of patho-
genic chromatin modifications at the peroxisome proliferator-
activated receptor-gamma coactivator 1 a (PGC-1a) promoter
that could be reversed using the deacetylase inhibitor Trichosta-
tin A (TSA), restoring mitochondrial biogenesis and enhancing
muscle oxidative capacity. By using the NO donor molsidomine,
we identify a physiological pathway that can rescue functionally
the bioenergetic defects of dystrophic muscles by shunting the
defective mitochondrial biogenesis. We describe a network
whereby the activation of SIRT1 causes the deacetylation of
PGC-1a ultimately leading to promotion of fatty acid oxidation
and a shift toward more oxidative muscle fibers. Thus, two
distinct therapeutic approaches yield similar functional effects
targeting different mitochondrial pathways.
RESULTS
Muscles of LGMD-2D Patients Show Altered
Mitochondrial Content and Activity
We found a reduction of mitochondrial DNA (mtDNA) in muscle
biopsies from LGMD-2D patients as compared to healthy age-
matched controls (Figure 1A), associated with reduced expres-
sion of the PGC-1amRNA, the master regulator of mitochondrial
biogenesis (Lin et al., 2005), and its downstream target, nuclear
respiratory factor 1 (NRF1) (Figure 1B) as well as reduced citrate
synthase (CS) activity (Figure 1C).
In LGMD-2D muscle sections, we also found, with respect to
healthy controls, reduced cytochrome c oxidase (COX) activity
and succinate dehydrogenase staining (SDH), used as good
proxies for mitochondrial activity (Figures 1D and 1E). Alto-
gether, these data indicate that mitochondrial number and
function in muscles of LGMD-2D patients are defective.
Muscles of a-SG Null Mice Show Altered Mitochondrial
Content and Activity
To investigate the mechanism of altered mitochondrial function
in LGMD-2D we relied on the a-SG null mouse model of the dis-
ease. We analyzed diaphragm and tibialis anterior (TA) muscles
of 5-month-old a-SG null mice compared to age-matched wild-
type (WT) mice as controls. We found a marked reduction of
mtDNA (Figures 2A and S1A) as well as of genes encoding
different electron transport chain subunits, namely cytochrome
b (CYT B), ATPase, and COX subunit IV (COX IV) (Figures 2B
and S1B). Consistently, the protein levels of COX IV and two
other mitochondrial proteins, porin (VDAC-1) and cytochrome c
oxidase subunit I (mtCO1), were lower in a-SG null than in control
mice (Figure 2C). The analysis of mitochondrial ultrastructure by
electron microscopy showed a reduction of mitochondrial den-
sity in a-SG null mice (Figure 2D), in agreement with decreased
CS activity (Figure 2E).To evaluate mitochondrial function, the respiratory rates ex-
pressed per tissue wet weight were assessed in saponin-per-
meabilized muscle fibers. As shown in Figures 2F and S1C, the
glutamate-malate-induced respiration (state 2) was significantly
reduced in a-SG null diaphragm versus control; further, in both
a-SG null diaphragm and TA, the ADP-driven glutamate-malate
respiration (state 3) was defective, and this impairment persisted
after the consecutive addition of succinate alone (state 3 + Succ)
or succinate plus rotenone (state 3 + Succ + Rot). These data
indicate a deficiency of the entire respiratory chain in a-SG null
mice, rather than damage to a specific complex. The differences
in mitochondrial activity appreciated with fibers analysis were no
longer observed when the respiratory rates were assessed by
comparing equal amounts of mitochondria isolated from a-SG
null and control skeletal muscles (Figure 2G). This indicates
that existing mitochondria have normal respiratory activity, and
the bioenergetics defect of a-SG null fibers resides in the
reduced mitochondrial content.
Of note, this mitochondrial defect was restricted to skeletal
muscle fibers and correlated to the disease stage, as other
tissues/organs such as liver, heart, and brown adipose tissue
(BAT) from a-SG null and control animals did not show differ-
ences in mtDNA content (Figure S1D). Similar results were
obtained inmdxmice, the mouse model of DMD, thus indicating
that the mitochondrial defect occurs selectively in skeletal mus-
cles and is associated with sarcolemmal instability (i.e., pertur-
bation of the dystrophin-sarcoglycan complex) (Figures S1E
and S1F).
Mitochondrial Biogenesis Is Impaired in Muscle of
a-SG Null Mice
The number of mitochondria is known to increase during muscle
growth (Laker et al., 2012). We found that in WT mice, mtDNA
was unchanged between 1.5 and 3 months, while it increased
significantly between 3 and 5 months, in both diaphragm and
TA (Figures 3A and S2A). Consistently, we found increased
PGC-1a mRNA levels in WT at 5 months when compared to
1.5-month-old mice (Figure 3B). In contrast, in a-SG null mus-
cles, we did not observe any increase in mitochondrial mass
(Figures 3A and S2A) nor in PGC-1a mRNA levels (Figure 3B)
during postnatal life, however, at 5 months, both PGC-1a
mRNA (Figure 3B and S2B) and proteins (Figure 3C) levels
were significantly lower in dystrophic mice than in controls.
Furthermore, the mRNA levels of NRF-1 and mitochondrial
transcription factor A (TFAM), were significantly reduced in
a-SG null mice (Figures 3D and S2B). These results suggest
that postnatally a-SG null muscles are unable to increase mito-
chondrial mass because the mitochondrial biogenesis pathway
is impaired.
PGC-1a is also known to slow calcium handling in skeletal
muscle (Summermatter et al., 2012); we found that a-SG null
muscles showed upregulation of calcium-signaling molecules,
such as calcium release-activated calcium modulator 1 (ORAI1)
and stromal interaction molecule 1 (STIM1) (Figure S2C). Thus,
the possibility that altered PGC-1a levels could influence mito-
chondrial calcium homeostasis in LGMD-2D and that this may
further contribute to the mitochondrial bioenergetics defect
cannot be excluded.Cell Reports 17, 3010–3023, December 13, 2016 3011
Figure 1. Muscles of LGMD-2D Patients Show Altered Mitochondrial Content and Activity
Analysis of bicep muscles of patients compared to control subjects.
(A) Analysis of mtDNA content (n = 9 for LGMD-2D patients and n = 10 for control subjects).
(B) Quantitative real-time PCR analysis of mitochondrial biogenesis genes (PGC-1a and NRF1) (n = 9 for LGMD-2D patients and n = 10 for control subjects).
(C) CS activity (n = 5 for LGMD-2D patients and n = 7 for controls subjects).
(D and E) Representative COX (D) and SDH (E) staining of muscle cryosections of one control and three LGMD-2D patients. Scale bar, 100 mm.
Values are expressed as mean ± SEM. *Versus control (*p < 0.05).We next directly assessed whether mitochondrial biogenesis
was altered by evaluating the response to cold exposure, a clas-
sical mitochondrial biogenetic stimulus (Hock and Kralli, 2009).
Cold exposure increased the mRNA levels of PGC-1a and
NRF1, and mitochondrial content in muscles of WT mice, but
not in a-SG null mice (Figures 3E and 3F, S2D, and S2E). These
data indicate that a-SG null muscles display a persistent defect
in mitochondrial biogenesis that accounts for a reduced mito-
chondrial content.
Muscles of a-SG Null Mice Show Epigenetic
Modifications on PGC-1a Promoter
We investigated the molecular determinants of the impaired
PGC-1a expression and mitochondrial biogenesis in a-SG null
mice. Dynamic chromatin modifications regulate PGC-1a
expression and hence the oxidative capacity of skeletal muscles
in pathological conditions, such as diabetes (Galmozzi et al.,
2013). We used chromatin immunoprecipitation analysis (ChIP)
to analyze three regulatory histone modifications at PGC-1a3012 Cell Reports 17, 3010–3023, December 13, 2016locus (Figure 4A). Specifically, we used antibodies that recognize
marks of active or repressed promoters, namely lysine 4 (Lys4),
methylation (H3K4me3), and lysine 27 (Lys27) methylation
(H3K27me3), respectively. No significant changes were
observed in H3K4me3 and H3K27me3 either in WT controls or
dystrophic mice (Figure S3). This evidence suggests that PGC-
1a promoter adopts a bivalent chromatin conformation that
poises for signal-dependent activation, as previously described
for ‘‘developmentally’’ regulated genes (Azuara et al., 2006;Bern-
stein et al., 2006; Mikkelsen et al., 2007). We assessed whether
the signal that resolves such a bivalency at the PGC-1a promoter
could be an increase in histoneH3 acetylation. Indeed, increased
H3 acetylation was observed in diaphragms from 5-month-old
WT control mice, but not in a-SG null mice, in two different re-
gions that map 430 bp upstream to the transcription start site
(TSS) and CRE site (Figure 4B). These data indicate that the
impairment of mitochondrial biogenesis in a-SG null mice is
accompanied by a chromatin conformation of the PGC-1a pro-
moter predictive of gene repression.
Figure 2. a-SG Null Mice Muscles Show Altered Mitochondrial Content and Activity
Analysis of a diaphragm of a 5-month-old a-SG null (/) compared to age-matched wild-type (n) mice.
(A) Analysis of mtDNA content (nR 12 per genotype).
(B) Quantitative real-time PCR analysis of genes encoding electron transport chain subunits (nR 5 per genotype).
(C) Immunoblot of VDAC, COX IV, mtCO1, and Actin (nR 6 per genotype). Densitometric quantification is provided.
(D) Electron microscopy analysis. Representative images are provided (nR 4 per genotype). Histogram represents the quantification of themitochondrial density
calculated as number of mitochondria per tissue area. Scale bar, 1 mm.
(legend continued on next page)
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To determine whether this epigenetic modification, that is
associated with defects in mitochondrial biogenesis in a-SG
null mice, could be pharmacologically reversed, we used the
pan-HDAC inhibitor (HDACi) Trichostatin A (TSA) (Consalvi
et al., 2013; Minetti et al., 2006). Increased histone acetylation,
which reflects the bioactivity of deacetylase inhibitors, was eval-
uated in the PGC-1a promoter at 430 bp upstream to the TSS
and CRE site. In both sites, acetylation levels were increased
by TSA treatment (Figure 4C). Consistently, PGC-1a mRNA
and protein levels (Figures 4D and 4E), as well as PGC-1a targets
genes (Figure 4F), were significantly enhanced after TSA admin-
istration, indicating the reactivation of the gene expression pro-
gram leading to mitochondrial biogenesis. Consequently, the
mitochondrial mass was boosted by TSA treatment as indicated
by the higher levels of mtCO1, and this resulted in a great
improvement of diaphragm oxidative capacity, as detected by
SDH and COX staining (Figures 4G–4I).
We and others have previously shown that nitric oxide (NO)
mediates a functional link between dystrophin and HDAC2 (Cac-
chiarelli et al., 2010; Colussi et al., 2008). Because NO has mito-
chondrial biogenetic properties (Lira et al., 2010; Ventura-Clapier
et al., 2008), we investigated whether NO delivery could reverse
the impaired mitochondrial biogenesis by upregulating PGC-1a
through promoter hyperacetylation. To this purpose, we used
the NO donor molsidomine, which can be incorporated into the
diet and delivered chronically in mouse models of muscular dys-
trophy (Buono et al., 2012; Cordani et al., 2014). Treatment for
4 months preserved skeletal muscle integrity, reduced fibrotic
tissue, and decreased inflammatory infiltrate (Figure S4A) in
agreement with studies that also demonstrate a functional re-
covery of spontaneous and forced motor activities (Buono
et al., 2012; Zordan et al., 2013).
Surprisingly, molsidomine did not modify H3 acetylation of
PGC-1a promoter at 430 bp upstream to TSS and CRE site in
a-SG null diaphragm (Figure 5A). Likewise, PGC-1amRNA levels
(Figure 5B), as well as the expression of PGC-1a target genes
(Figure S4B) and the mitochondrial density (Figures 5C), did
not change after molsidomine treatment. The protein analysis
confirmed the unchanged levels of PGC-1a and mitochondrial
markers after molsidomine treatment (Figure 5D). These obser-
vations were not exclusive to the diaphragm as similar results
were obtained in TA of a-SG null mice (Figures S4C and S4D)
and clearly indicate that, at variance with mdx mice, chronic
administration of NO, supplemented with the diet, does not
target the pathogenic chromatin conformation of a-SG null
mice and does not enhance mitochondrial biogenesis.
NO Improves Mitochondrial Function in the Absence of
Mitochondrial Biogenesis
Despite the absence of mitochondrial biogenesis, the respira-
tory capacity of muscle fibers from diaphragm and TA of mol-
sidomine-treated a-SG null mice was significantly enhanced(E) CS activity (nR 4 per genotype).
(F) Mitochondrial respiration in permeabilized diaphragm muscle fibers (nR 5 pe
(G) Mitochondrial respiration from isolated diaphragm mitochondria (n = 8 per ge
Values are expressed as mean ± SEM. *Versus WT (*p < 0.05, **p < 0.01, ***p <
3014 Cell Reports 17, 3010–3023, December 13, 2016(Figures 5E and S4E). Consistently, the production of OxPhos
ATP by mitochondria isolated from a-SG null diaphragm
treated with molsidomine was significantly higher than in un-
treated a-SG null muscles (Figure S4F). Thus, NO improved
mitochondrial respiratory capacity while not increasing mito-
chondrial density.
Because improved OxPhos capacity can result in the varia-
tions of glycolytic and oxidative muscle fiber proportions (Feige
et al., 2008), we evaluated whether NO promoted fiber-type
switching. To this end, the contractile phenotype of a-SG null
and WT mice was assessed by immunofluorescence of type I
and IIa myosin heavy chains (MyHCs), both markers of slow-
twitch fibers. a-SG null diaphragm displayed reduced expres-
sion of MyHC IIa, but not MyHC I, compared toWT andmolsido-
mine-restored MyHC IIa levels (Figure 5F). Levels of MyHC IIa
were increased by molsidomine in TA as well (Figure S4G).
Consistently, SDH staining revealed that the proportion of
blue-stained oxidative fibers in TA was higher in molsidomine-
treated a-SG null mice than in untreated a-SG null mice
(Figure S4H).
Molsidomine treatment increased the expression of medium-
and long-chain acyl-CoA dehydrogenases (MCAD and LCAD,
respectively) and pyruvate dehydrogenase kinase 4 (PDK4) in
both the diaphragm and TA of a-SG null mice (Figures 5G
and S5A). By contrast, the expression of genes controlling
glycolysis, Krebs cycle, and mitochondrial function were not
affected by molsidomine treatment (Figure S5B). Thus, the fiber
switch induced by NO was associated with an increased
expression of genes promoting the use of fatty acid over
glucose (i.e., enzymes decreasing the utilization of pyruvate
and increasing the flux of fatty acid in the muscle). Consistently,
in myotubes, NO improved palmitate oxidation (Figure 5H)
without affecting mitochondrial content and myogenic differen-
tiation (Figure S5C).
Because SIRT1 is a key regulator of lipolysis and FAO (Ger-
hart-Hines et al., 2007), we assessed whether it can be modu-
lated by NO. In diaphragm of a-SG null mice, molsidomine
significantly enhanced SIRT1 mRNA expression (Figure 6A) re-
sulting in decreasing acetylated levels of PGC-1a protein, a
known substrate of SIRT1 (Figure 6B). The acetylation status
of PGC-1a is considered a marker of SIRT1 activity in vivo
because PGC-1a activity is described to be positively regulated
by SIRT1-mediated deacetylation (Lagouge et al., 2006; Rodg-
ers et al., 2005). However, NAD+ is a rate limiting co-substrate
for SIRT1, and altered NAD+ levels in a-SG null muscle might
affect SIRT1 activity. As shown in Figure 6C, NAD+ levels were
increased in the diaphragm of a-SG null mice, thus indicating
that NAD+ was not a limiting factor to SIRT-1 activity in dystro-
phic muscle. Treatment with molsidomine resulted in mild
reduction of NAD+ levels, probably caused by increased con-
sumption, suggesting that NO stimulation of SIRT1 was inde-
pendent of NAD+ levels.r genotype).
notype).
0.001). See also Figure S1.
Figure 3. a-SG Null Mice Exhibit a Persistent Inhibition of Mitochondrial Biogenesis Process
(A) Analysis ofmtDNA content in diaphragm ofWT and a-SG/mice during postnatal life (1.5, 3, and 5months of age). Values are expressed asmean ±SEM (nR
3 per group). *Versus each time point. (**p < 0.01).
(B) Quantitative real-time PCR analysis of PGC-1a in diaphragm ofWT and a-SG/mice during postnatal life (1.5 and 5months of age) (nR 4 per group). *Versus
WT at 1.5 months of age (**p < 0.01); +versus WT at 5 months of age (+++p < 0.001).
(C) Immunoblot of PGC-1a and actin (n = 4 per genotype). Densitometric quantification is provided. *Versus WT (**p < 0.01).
(D) Quantitative real-time PCR analysis of NRF1 and TFAM in diaphragm of 5-month-old WT and a-SG/ mice (nR 3). * versus WT (***p < 0.001).
(E and F) Quantitative real-time PCR analysis of mitochondrial biogenesis genes after 24 hr (E) and mtDNA content in diaphragm after 72 hr (F) of cold exposure
(4C) in diaphragm of 5-month-old WT and a-SG/mice relative to corresponding unstimulated controls (nR 3–4). *Versus unstimulated controls (dashed line,
WT mice; dotted line, a-SG/ mice) (**p < 0.01).Values are expressed as mean ± SEM. See also Figure S2.SIRT1 activators enhance metabolic processes associated
with low energetic status through AMPK activation (Chen and
Guarente, 2007; Feige et al., 2008). In myotubes, short-term
exposition to NO did not activate AMPK (Figure S6A); however,
in dystrophic mice, molsidomine increased phosphorylation of
AMPK and expression of the AMPK target, FOXO3a, (Figures6D and 6E), supporting the idea that NO changes the metabolic
status of dystrophic muscle and indirectly activates AMPK.
These effects ofmolsidominewere not restricted to diaphragm
as similar data on SIRT1 expression levels, PGC-1a acetylation,
and AMPK phosphorylation were also detected in TA muscle in
response to molsidomine treatment (Figures S6B–S6D).Cell Reports 17, 3010–3023, December 13, 2016 3015
Figure 4. a-SG Null Mice Show Inhibitory
Epigenetic Modifications on PGC-1a Pro-
moter Reverted by TSA
(A) Schematic representation of PGC-1a proximal
promoter with primers used to amplify TSS-430
and CRE regions.
(B and C) ChIP analysis of PGC-1a proximal pro-
moter performed in diaphragm homogenates at
1.5 and 5 months of age (B) or after TSA treatment
(C) (n = 4 per genotype or treatment). Graphs show
quantitative PCR values normalized against the
input DNA and relative to either WT 1.5 months (B)
or vehicle-treated (C) mice (**p < 0.01). AcH3: H3
acetylation; IgG: immunoglobulin.
(D) Quantitative real-time PCR analysis of PGC-1a
in diaphragm of a-SG/mice after TSA or vehicle
treatment (n = 4). *Versus vehicle-treated mice
(*p < 0.05, **p < 0.01, ***p < 0.001).
(E) Immunoblot of PGC-1a and actin after TSA or
vehicle treatment (n = 4). Densitometric quantifi-
cation is provided. *Versus vehicle-treated mice
(**p < 0.01).
(F) Quantitative real-time PCR analysis of NRF1,
TFAM, CYT B, and ERRa genes in diaphragm of
a-SG/mice after TSAor vehicle treatment (n=4).
*Versus vehicle-treatedmice (*p < 0.05, **p < 0.01).
(G) Immunoblot of mtCO1 and actin after TSA or
vehicle treatment (n = 4). Densitometric quantifi-
cation is provided. *Versus vehicle-treated mice
(*p < 0.05).
(H and I) Representative COX (H) and SDH (I)
staining of vehicle- and TSA-treated diaphragms.
Scalebars, 100mm.Stainingquantification (n=4) is
provided. *Versus vehicle-treated mice (*p < 0.05).
Values are expressed as mean ± SEM. See also
Figure S3.NOTreatment Induces a SIRT-1-Dependent Shift toward
More Oxidative Muscle Fibers
To assess whether SIRT1 activation is required for the induction
of fatty acid oxidation and the shift toward more oxidative meta-
bolism induced by NO, a-SG null mice were treated with or
without molsidomine for 4 months in the presence or absence,3016 Cell Reports 17, 3010–3023, December 13, 2016in the last 2 months, of nicotinamide
(NAM), a specific SIRT1 inhibitor (Avalos
et al., 2005; Green et al., 2008).
NAM administration abolished com-
pletely the effect of molsidomine on
PGC-1a protein, restoring the acetylation
levels to those observed in the untreated
a-SG null mice (Figure 7A). In addition,
NAM blocked the ability of molsidomine
to enhance ADP-driven (state 3) and suc-
cinate-stimulated respiratory rates (state
3 + S and state 3 + S + Rot) (Figure 7B).
In line with these data, NAM prevented
the (NO-dependent) induction of the
genes promoting FAO pathway, peroxi-
some proliferator-activated receptor a
(PPARa), PDK4, and LCAD (Figure 7C),
as well as the enhancement of AMPK ac-tivity (Figure 7D), suggesting that the inhibition of SIRT1 results in
the complete loss of the metabolic shift induced by NO.
We conclude from these results that NO improves mitochon-
drial function and promotes fiber switch in a-SG null mice via a
pathway requiring SIRT1 and leading to AMPK activation
and FAO.
(legend on next page)
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Figure 6. Molsidomine Affects Muscle
Metabolism through SIRT1 Modulation and
AMPK Activation
Analyses of a-SG/ diaphragm treated or not
with molsidomine.
(A) Quantitative real-time PCR analysis of SIRT1
relative to WT (dashed line) (nR 8 per group).
(B) Protein homogenates immunoprecipitated (IP)
with PGC-1a antibody and analyzed by immuno-
blot (IB) for lysine acetylation levels compared to
total protein (n R 8 per group). Densitometric
quantification relative to WT (dashed line) is pro-
vided.
(C) Determination of NAD+/NADH ratio (nR 4 per
group).
(D) Representative immunoblot for phospho-
AMPK (pAMPK) (Thr172) and total AMPK. The
graph shows the pAMPK/total AMPK (n = 7 per
group). Densitometric quantification is provided.
(E) Representative immunoblot for FOXO3a and
actin (n = 4 per group). Densitometric quantifica-
tion is provided.
Values are expressed as mean ± SEM. *Versus
untreated a-SG/ mice (*p < 0.05, **p < 0.01,
***p < 0.001). See also Figure S6.DISCUSSION
In this study, we demonstrate a mitochondrial defect in LGMD-
2D, and we characterize it functionally and molecularly,
providing key information on LGMD-2D pathophysiology and
possible strategies for the development of therapeutic
approaches.Figure 5. NO Donor Molsidomine Modulates Mitochondrial Function without Affecting Mitocho
Analyses of a-SG/ diaphragm treated or not with molsidomine.
(A) ChIP analysis of PGC-1a proximal promoter in diaphragm homogenates. Graphs show quantitative PCR v
WT (dashed lines) (n = 4 per group).
(B and C) Quantitative real-time PCR analysis of PGC-1a mRNA (B) and analysis of mtDNA content (C) relat
(D) Immunoblot of PGC-1a, mtCO1, COX IV, and actin in diaphragm homogenates (n = 4 per group). Densitom
(E) Mitochondrial respiration in permeabilized muscle fibers (n = 6 per group). *Versus untreated a-SG/ m
(F) Representative MyHCs immunostaining on diaphragm sections of WT and a-SG/ mice treated or not w
MyHC IIa (green) fibers (nR 3 per group). Scale bar, 100 mm. *Versus WT (**p < 0.01); +versus untreated a-
(G) Quantitative real-time PCR analysis of genes of fatty acid oxidation (nR 5 per group).
(H) Palmitate oxidation rate in C2C12 cells treated or not (NT) with NO donor (SIN-1, see the Supplemen
(*p < 0.05).
Values are expressed as mean ± SEM. See also Figures S4 and S5.
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as determinant in many muscle disorders
(Millay et al., 2008; Ripolone et al., 2015),
and some aspects of it have been investi-
gated in muscular dystrophy (Chen et al.,
2000; Godin et al., 2012; Guevel et al.,
2011; Percival et al., 2013; Pescatori
et al., 2007; Rybalka et al., 2014) suggest-
ing that targeting mitochondrial dysfunc-
tions ameliorates the dystrophic pheno-
type (Millay et al., 2008; Reutenauer
et al., 2008). However, no information has
been reported yet on the mitochondrialphenotype in the skeletal muscles of LGMD-2D. In the present
study,we identify in LGMD-2Da specificmitochondrial deficiency
associated with the impairment of the dystrophin-glycoprotein
complex and sarcolemmal instability. In LGMD-2D patients, we
observed reduced mitochondrial content and expression of key
regulators of mitochondrial biogenesis, as well as an impaired
OxPhos activity. In the LGMD-2D a-SG null mice, muscles dis-
played low oxidative metabolism, dependent on reduced levelsndrial Biogenesis
alues normalized against the input DNA relative to
ive to WT (dashed lines) (nR 4 per group).
etric quantification relative to a-SG/ is provided.
ice (*p < 0.05).
ith molsidomine. Percentage of MyHC I (red) and
SG/ mice (++p < 0.01).
tal Experimental Procedures) (n = 3). *Versus NT
Figure 7. The NO-Induced Shift toward More Oxidative Muscle Fiber Is SIRT1-Dependent
Analyses of a-SG/ diaphragm treated or not with molsidomine in presence or absence of NAM.
(A) Homogenates were immunoprecipitated (IP) with PGC-1a antibody and analyzed by immunoblot (IB) for lysine acetylation levels compared to total protein (n
R 4 per group). Densitometric quantification is provided.
(B) Mitochondrial respiration in permeabilized muscle fibers (nR 4 per group).
(C) Quantitative real-time PCR analysis of genes involved in fatty acid oxidation (nR 4 per group).
(D) Representative immunoblot for phospho-AMPK (pAMPK) (Thr172) and total AMPK. The graph shows the pAMPK/total AMPK (nR 4 per group).
Values are expressed as mean ± SEM. *Versus a-SG/ mice (*p < 0.05, **p < 0.01, ***p < 0.001); +versus a-SG/ molsidomine-treated mice (+p < 0.05,
++p < 0.01, +++p < 0.001).of PGC-1a and its target genes, leading to a decreasedmitochon-
drial number and reduced slowfiber-type composition.Mitochon-
drial biogenesiswas not inducedby classical physiological stimuliincluding development and cold (Hock and Kralli, 2009; Laker
et al., 2012), indicating a persistent and severe defect. This sug-
gests that a-SG null muscles are unable to cope with metabolicCell Reports 17, 3010–3023, December 13, 2016 3019
environmental conditions that require mitochondrial biogenesis.
Interestingly, in the a-SG null mice, a ‘‘mitochondrial crisis’’ has
beenobserved (Chenet al., 2000), and the lowmitochondrial num-
ber resulting from the impaired biogenesis process, described
here, may be considered the most likely cause.
We next investigated the mechanism responsible for the
impairment of the mitochondrial biogenetic pathway. In dystro-
phic condition, HDACs have an increased activity compared to
control, and impaired NO production could contribute to the
dysregulation of epigenetic pathways involving HDACs (Colussi
et al., 2008, 2009; Illi et al., 2009).
We found that the defective mitochondrial biogenesis de-
pended on epigenetic modifications of the PGC-1a promoter
that was characterized by a condensed and repressed chromatin
structure. Histone acetylation is a hallmark of active chromatin
structure, as it allows chromatin relaxation and efficient gene
transcription by reversing the positive charges on histones
(Hebbes et al., 1988).Weobserved thata-SGnullmuscles exhibit
lower levels of H3 acetylation at the PGC-1apromoter. Increased
H3 acetylation, by using the panHDACi TSA, could reverse the
epigenetic profile (promoter bivalency) at the PGC-1a locus and
promote PGC-1a transcription, thereby restoring mitochondrial
biogenesis and the oxidative capacity of a-SG null muscles.
Therapeutic approaches modulating PGC-1a expression in
muscle have yielded conflicting results. PGC-1a gene transfer
in 6-week-old mdx mice increases mitochondrial mass (Godin
et al., 2012) and mdx mice overexpressing PGC-1a selectively
in muscle cells show significant induction of OxPhos genes
and improved muscle function (Chan et al., 2014). Conversely
PGC-1a gene transfer in young (3-week-old) mdx mice displays
only a relatively modest expression of oxidative genes (Hollinger
et al., 2013). These discrepancies may be explained assuming
that oxidative response depends on the genetic approach
used for PGC-1a manipulation and on the time of induction.
Based on our data, we suggest that an alternative therapeutic
approach in muscular dystrophy might be the reactivation of
the mitochondrial biogenesis by remodeling chromatin structure
at the PGC-1a promoter with HDACi drugs, rather than PGC-1a
overexpression.
Given the established link between NO and HDAC (Colussi
et al., 2008), we tested the efficacy of NO, which has previously
shown beneficial effect on dystrophic muscle and on mitochon-
drial biogenetic activity (Lira et al., 2010; Nisoli et al., 2003, 2007;
Tidball and Wehling-Henricks, 2014; Ventura-Clapier et al.,
2008). The NO donor molsidomine did not modify the acetylation
status of PGC-1a promoter nor the mitochondrial content. Still,
NO significantly improved oxidative metabolism and energy
expenditure, suggesting the existence of a bioenergetics mech-
anism, activated by NO, that is able to act as a possible salvage
pathway when mitochondrial biogenesis is impaired.
We found that NO enhances fatty acid oxidation and promotes
FAO genes transcription, especially PPARa and PPARa target
genes, PDK4 and LCAD (Ashmore et al., 2015; Degenhardt
et al., 2007; Feige et al., 2008). This drives an oxidative program,
which induces a switch towardmore oxidative muscle fibers. NO
was supplemented with the diet at low concentrations (Sciorati
et al., 2011) and its effects could have been due to upregulation
of intra-mitochondrial pathways of FAO as it occurs with low/3020 Cell Reports 17, 3010–3023, December 13, 2016moderate doses of nitrate. In these conditions, nitrates, through
NO production, enhance muscle FAO, increasing expression
and transcriptional activity of PPARa and b/d, and driving intra-
mitochondrial changes, such as upregulation of malonil-CoA
decarboxylase and muscle carnitine concentrations, but without
affecting mitochondrial volume (Ashmore et al., 2015).
This phenotype is similar to that described using the SIRT1-
specific activator SRT1720, which has a limited activity on
mitochondrial density but promotes oxidative metabolism con-
trolling FAO (Feige et al., 2008). Our results indicate that NO
acted as SIRT1 activator, and the deacetylation of PGC-1a
was the molecular key step leading to activation of PPARa axis
and to the oxidative shift, hence SIRT1 and the deacetylation
of PGC-1a are essential for NO to increase PGC-1a activity.
SIRT1 activation occurs in low energy conditions such as fast-
ing or calorie restriction (Gerhart-Hines et al., 2007; Rodgers
et al., 2005), and SIRT1 activators can, in turn, stimulate path-
ways associated with low energy status acting as calorie-restric-
tion mimetic (Barger et al., 2008; Feige et al., 2008). Dystrophic
mice treated with molsidomine showed high phosphorylation
levels of AMPK and an induction of FOXO3a, a specific target
of AMPK. However, acute treatment with NO did not directly
activate AMPK in myotubes, thus suggesting that NO, via
SIRT1, induces key metabolic changes accounting for AMPK
activation, which in turn sustains and amplifies FAO. While we
cannot exclude possible additional off target actions of molsido-
mine, our data define NO as a SIRT1 activator that can correct a
bioenergetics deficit in dystrophic muscles, ameliorating fatty
acid consumption by deacetylation of PGC-1a and induction of
metabolic adaptation associated with AMPK activation.
It is important to note that the effect of NO on the activation of
SIRT1-PGC-1a pathway persisted over time (20 weeks). This
prolonged metabolic action, inducing a therapeutic fiber-type
switch, together with the positive effects on the self-renewal abil-
ity of satellite cells, inflammatory infiltrate, and fibro-adipogenic
precursors cells (Buono et al., 2012; Cordani et al., 2014; Zordan
et al., 2013) reinforces the notion that the donation of NO is a
valid therapeutic tool for muscular dystrophy.
In view of the importance of reestablishing mitochondrial ho-
meostasis in muscular dystrophy and considering the effect of
TSA on mitochondrial biogenesis we describe here, we
suggest that a combination of NO with deacetylase inhibitors is
an interesting therapeutic option to be explored. This appears
of particular relevance for a disease such as LGMD-2D for which
corticosteroid therapy is not a valuable tool and other therapies
directly addressing the dystrophic muscle are still missing.EXPERIMENTAL PROCEDURES
Animals Experiments
C57BL/6 a-SG null mice and WT mice were handled in accordance with Euro-
pean Directive (2010/63/UE) and the Italian law on animal care (D.L. 26/2014).
The experimental protocols were described in details in the Supplemental
Experimental Procedures.
Human Muscle Sample
A total of 11 control and 10 LGMD-2Dmuscle samples were obtained from the
‘‘Biobank of Muscle Tissue, Peripheral Nerve Tissue, DNA, and Cell Lines’’ of
the Neuromuscular and Rare Diseases Unit, Scientific Institute IRCCS
Fondazione Ca’ Granda- Ospedale Maggiore Policlinico (Milano, Italy), which
is part of the Telethon Genetic Biobank network.
Oxygen Consumption Measurement
Oxygen consumption was measured using Oroboros O2K oxygraph
(Oroboros Instruments) as described in the Supplemental Experimental
Procedures.
PGC-1a Acetylation Assay
PGC-1a acetylation was detected by immunoprecipitation in TA and dia-
phragm muscles as described (Woldt et al., 2013). In brief, muscle tissues
were homogenized in a buffer containing 50 mM Tris-HCl (pH 7.4), 68 mM su-
crose, 50mMKCl, 10mMEDTA, 0.2%BSA, protease, and phosphatase inhib-
itor mixture. PGC-1a protein was immunoprecipitated from 500 mg of protein
homogenate with Santa Cruz antibody against PGC-1a antibody (Santa Cruz
Biotechnology, sc-13067, 2 mg per sample) followed by western blot analysis
using antibody against acetyl-lysine (1:2,000, Cell Signaling 944, Cell Signaling
Technology) and PGC-1a (Cell Signaling 4259). To demonstrate the specificity
of the Santa Cruz antibody, we have immunoprecipitated muscle lysate with
the Santa Cruz antibody and detected the PGC-1a band with two different an-
tibodies, Cell Signaling 4259 and Millipore, AB3242 (Merck Millipore). The
respective IgG as negative control has been used, as shown in the Figure S7.
Chromatin Immunoprecipitation
ChIP assay was performed as previously described (Albini et al., 2013) withmi-
nor modifications indicated in the Supplemental Experimental Procedures and
using primers specified in Table S2.
Quantitative Real-Time PCR and DNA Quantification
Total RNA and mitochondrial DNA were isolated from human and mouse mus-
cles as described in the Supplemental Experimental Procedures and amplified
using the primers listed in Table S1.
Statistical Analysis
Statistical significance of raw data between the groups in each experiment
was evaluated using unpaired Student’s t test (single comparisons) or one-
way ANOVA followed by Bonferroni or Tukey post-tests (multiple compari-
sons). When data are not normally distributed, the Mann-Whitney test was
used and, when indicated, data belonging from different experiments were
represented and averaged in the same graph. The GraphPad Prism soft-
ware package (Graph Software) was used. The results are expressed as
means ± SEM of the indicated n values. A probability of <5% (p < 0.05)
was considered to be significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and two tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2016.11.044.
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